Target intelligence / Profile preview

Epithelial surface and extracellular matrix proteins of gastric mucosa

Molecular classification
Other
01

Overview

Epithelial surface and extracellular matrix proteins of gastric mucosa refers to a heterogeneous group of proteins, including mucins, collagens, and laminins, that constitute the lining and structural framework of the stomach wall (DrugBank, DB01294). In a pharmacological context, these proteins act as a target for mucosal protectants such as bismuth salts and sucralfate (StatPearls, NBK537076). These agents bind to the proteins exposed at the site of gastric erosions or ulcers, forming a stable, insoluble complex that serves as a physical shield against corrosive gastric acid and proteolytic enzymes like pepsin (PubMed, 7038447). Furthermore, this coating can interfere with the colonization of Helicobacter pylori by masking the adhesion sites the bacteria use to attach to the epithelium (PubMed, 1530702). While not a single molecular entity, this protein group is critical for maintaining gastric integrity and facilitating the healing of the mucosal layer.

Other names
Gastric mucosal proteinsGastric extracellular matrixGastric epithelial surface proteinsGastric mucosal barrier proteins
02

Mechanism of action

Mucosal protectants bind to the proteinaceous exudate (such as albumin and fibrinogen) at ulcer sites and the gastric epithelial surface to form a protective physical barrier that prevents damage from gastric acid and pepsin, while also inhibiting the adherence of Helicobacter pylori (DrugBank, DB01294; StatPearls, NBK537076).

03

Biological functions

Cell adhesion (PubMed, 1530702)Barrier function (DrugBank, DB01294)Mucosal protection (StatPearls, NBK537076)Structural integrity (PubMed, 7038447)
04

Disease associations

Infection (Helicobacter pylori) (PubMed, 1530702)Inflammation (Gastritis) (StatPearls, NBK537076)Peptic ulcer disease (DrugBank, DB01294)Gastroesophageal reflux disease (GERD) (PubMed, 2850244)
05

Safety considerations

Bismuth toxicity (encephalopathy) with chronic high doses (StatPearls, NBK537076)Blackening of stools and tongue (DrugBank, DB01294)Salicylate toxicity (PubMed, 2850244)Constipation (Sucralfate) (StatPearls, NBK537076)Drug-drug interactions due to impaired absorption of tetracyclines or fluoroquinolones (PubMed, 2850244)
06

Interacting drugs

Bismuth subsalicylate (DrugBank, DB01294)

3 more in the full profile.

Beyond the preview

Go deeper on Epithelial surface and extracellular matrix proteins of gastric mucosa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epithelial surface and extracellular matrix proteins of gastric mucosa.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call